The use of silica coated MnO nanoparticles to control MRI relaxivity in response to specific physiological changes.
about
Nanoparticle-based systems for T(1)-weighted magnetic resonance imaging contrast agentsIn vitro cytotoxic evaluation of MgO nanoparticles and their effect on the expression of ROS genesSilica-F127 nanohybrid-encapsulated manganese oxide nanoparticles for optimized T1 magnetic resonance relaxivity.Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapySelf-organized Mn(2+)-Block Copolymer Complexes and Their Use for In Vivo MR Imaging of Biological Processes.Effects of Mesoporous Silica Coating and Post-Synthetic Treatment on the Transverse Relaxivity of Iron Oxide NanoparticlesNonporous Silica Nanoparticles for Nanomedicine Application.Mn₃[Co(CN)₆]₂@SiO₂ core-shell nanocubes: novel bimodal contrast agents for MRI and optical imaging.pH-Activatable MnO-Based Fluorescence and Magnetic Resonance Bimodal Nanoprobe for Cancer Imaging.Quantitation of oxidative stress gene expression in MCF-7 human cell lines treated with water-dispersible CuO nanoparticles.Dual-modality, fluorescent, PLGA encapsulated bismuth nanoparticles for molecular and cellular fluorescence imaging and computed tomography.Paramagnetic inorganic nanoparticles as T1 MRI contrast agents.Multifunctional UCNPs@MnSiO3@g-C3N4 nanoplatform: improved ROS generation and reduced glutathione levels for highly efficient photodynamic therapy.Engineering of inorganic nanoparticles as magnetic resonance imaging contrast agents.Surface engineering of bismuth nanocrystals to counter dissolution.AS1411 aptamer-conjugated Gd2O3:Eu nanoparticles for target-specific computed tomography/magnetic resonance/fluorescence molecular imagingSilica-based multifunctional nanodelivery systems toward regenerative medicine
P2860
Q26824262-3BF00C24-0800-427D-9C25-C1CD45D315D7Q28393632-93D04707-4D7A-4618-B415-33FA88F968F8Q30689242-FEBB5195-31FE-46AA-B430-5C158F245C8CQ30830508-D73EBC79-9C91-4153-91CA-A5B5F6A7EBAEQ34421475-E62DAEC4-02E1-483B-828F-E12B8F11B7B9Q36960523-7A08F813-7622-4848-B720-D101068B25B5Q37131939-07901EAD-272B-4DE7-B99D-DD18DAA67B45Q37165329-B8A63D36-A882-41D0-A448-6C5118969EB1Q38792639-C82BD34A-F8C4-4D8C-AA44-5503DCBF8857Q39007203-ED69326D-6C15-41F9-BE31-2BE84E9A0666Q42558508-539157C2-F909-414C-936F-74E8D34979FEQ45848579-242DB12E-71E4-424C-95CB-C0EF5FD4B63CQ46275394-FBA24699-6901-46D0-B0DB-36A27B3A44B8Q47409412-E87E34F5-7643-4E3E-94B2-4DBCA021391BQ50253525-D3484B75-3735-41E5-B19D-92C402DFBD6AQ57353070-6B6A008C-D2AF-4B13-91B6-FE7AAE080980Q57367659-CF37771F-2B35-4504-8C21-783F8097AB7F
P2860
The use of silica coated MnO nanoparticles to control MRI relaxivity in response to specific physiological changes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The use of silica coated MnO n ...... pecific physiological changes.
@ast
The use of silica coated MnO n ...... pecific physiological changes.
@en
type
label
The use of silica coated MnO n ...... pecific physiological changes.
@ast
The use of silica coated MnO n ...... pecific physiological changes.
@en
prefLabel
The use of silica coated MnO n ...... pecific physiological changes.
@ast
The use of silica coated MnO n ...... pecific physiological changes.
@en
P2093
P2860
P1433
P1476
The use of silica coated MnO n ...... pecific physiological changes.
@en
P2093
Alan P Koretsky
Der-Yow Chen
Kannan M Krishnan
Nadia Bouraoud
Stephen J Dodd
Yi-Cheng Lee
P2860
P304
P356
10.1016/J.BIOMATERIALS.2012.01.062
P577
2012-02-17T00:00:00Z